Abstract: Arginine vasopressin (AVP) is a cyclic nonapeptide synthesized exclusively by neurosecretory cells of the central nervous system (CNS). Two functionally distinct vasopressinergic systems can be defined based on differences in the sites of action and release of AVP. The peripheral vasopressinergic system encompasses the sites of action for AVP released into peripheral circulation (e.g. vascular smooth muscle, liver, kidney) from nerve terminals in the posterior pituitary. Peripherally circulating AVP is responsible for the classic endocrine functions ascribed to this neurohormone (e.g. vasoconstriction, glycogen metabolism, antidiuresis). The central vasopressinergic system, on the other hand, includes the sites of AVP synthesis and release within the CNS, where AVP acts as a neuromodulator/neurotransmitter regulating an array of CNS-mediated functions (e.g. learning and memory, neuroendocrine reactivity, social behaviors, circadian rhythmicity, thermoregulation, and autonomic function). Historically, pharmaceutical interest has focused on drug development efforts that sought to exploit the peripheral effects of AVP. Evidence, however, from clinical studies and animal models of CNS disorders has directly implicated disturbances in vasopressinergic activity in the pathophysiology of a number of human psychiatric disorders (mood, anxiety, and cognitive disorders). This review will examine the available evidence of central vasopressinergic system involvement in psychiatric disorders, and the potential opportunities for development of novel psychopharmaceuticals around this system will be discussed. Specific lines of evidence will be presented which rationalize each AVP receptor subtype (V 1 R or V 1a , V 2 R, V 3 R or V 1b ) as a molecular target for particular psychiatric indications.
INTRODUCTION
Oliver and Schafer were the first to describe the endocrine effects of AVP over a hundred years ago with the observation that bovine pituitary extracts elicited a potent vasopressor effect when injected into an anaesthetized dog [1] . Shortly thereafter, Howell, Schafer and Vincent demonstrated that this vasopressor effect was restricted to extracts from the posterior lobe specifically, leading researchers to focus on extracts from this lobe for many years. Vasopressin derives its name from this pressor effect on the cardiovascular system. Within twenty years of Oliver and Schafer's observations, the endocrine effects of posterior pituitary preparations were extended to include other endocrine functions. In particular was the regulation of water reabsorption in the kidneys that ultimately led to an alternate nomenclature for vasopressin as the antidiuretic hormone (ADH). Pituitary extracts were shown to decrease urinary output, increase the density of the urine, and reduced thirst [2] . As early as 1913, physicians had already exploited the antidiuretic effects of posterior pituitary preparations clinically as a treatment for patients with diabetes insipidus [3, 4] .
By the early 1950s, the specific peptide fraction of pituitary extracts had been isolated which contained the endocrine activities attributed to vasopressin [5] . This laid the foundation for subsequent success in the elucidation of the AVP structure and first complete synthetic preparation this peptide by Vincent du Vigneaud and his colleagues [6] . The significance of this synthesis, and that of oxytocin (OT), earned du Vigneaud the Nobel Prize in 1954, and is thought to have fueled the emergence of the modern field of protein chemistry. With the structure in hand, the field of AVP research soon entered into a period of substantial structure activity analysis and analog design, which would produce the pharmacological tools that would ultimately help define the now numerous physiological roles for AVP, and enable the discovery and characterization of AVP receptors.
An appreciation for the direct effects of AVP on central nervous system (CNS) function did not emerge until 1965 and the seminal observations of David de Wied, who had been investigating the relationships between conditioned behavior and neuro-endocrine mechanisms. In the oft referenced study, de Wied demonstrated that removal of the posterior and intermediate lobes of the pituitary accelerated extinction of conditioned avoidance behavior in rats without affecting its acquisition, an effect that could be normalized by peripheral administration of crude pituitary extract (pitressin) or lysine vasopressin (LVP) [7] . This provided the first evidence for a direct effect of AVP on CNS function. Prior to this, evidence supporting the central effects of pituitary peptides had been limited to a few examples. Central administration of ACTH of α-MSH had been shown to stimulate the stretching and yawning syndrome in dogs and rabbits, and general neurotropic activity had been noted for β-MSH, substance P, and bradykinin [8] [9] [10] . Ultimately, these observations would help to provide the foundation of what became known as the neuropeptide concept, or 'neuropeptide hypothesis,' championed by de Wied, Dorothy Krieger, and others [11, 12] .
In almost 40 years of subsequent research following de Wied's observations, our understanding of AVP actions in the CNS has broadened to include other behaviors (e.g. social, reproductive, rewarded), in addition to the regulation of circadian rhythms, autonomic functions (e.g. thermoregulation, cardiovascular regulation) and the hypothalamicpituitary-adrenal (HPA) axis. With the development of selective peptide analogs of AVP, the cloning and characterization of AVP receptor subtypes, and the neuroanatomical elucidation of a vasopressinergic network within the CNS, investigators have now firmly established AVP as a bona fide neuromodulator/neurotransmitter of the CNS. Today, it is commonly acknowledged that this 'central vasopressinergic system' is functionally and physiologically distinct from the classic endocrine roles established for AVP released into peripheral circulation from the posterior pituitary.
Not surprisingly, as the understanding of AVP effects on CNS function has increased, so has clinical interest in the central vasopressinergic system as a potential target for CNS drug discovery. Early interest in the central vasopressinergic system focused on the enhancing effects of AVP on cognitive function suggested by initial studies in animals. From 1981 to 1998, over thirty small clinical studies were conducted that examined the effects of clinically approved peptide analogs of AVP (used for peripheral indications) on learning and memory in healthy patients, and affirmed the general ability of AVP to enhance declarative memory [13] . A number of studies have also sought to examine the effects of AVP analogs in elderly patients with normal cognitive decline or other age-related disease impacting cognitive function, such as Alzheimer's disease (AD). Small clinical trials have also been run which have examined the efficacy of AVP analogs for a variety of cognitive disorders, but the results of these studies have been less consistent.
To date, clinical studies have not exploited the importance of AVP in other more complex behaviors. Evidence from clinical studies and animal models of human psychiatric disease has begun to reveal novel opportunities for the central vasopressinergic system as a therapeutic target for psychiatric disorders. These include depression, anxiety, and schizophrenia. This review will briefly explore the role of the central vasopressin system in mediating CNS functions with particular attention placed on examining the evidence, from both animal and clinical studies, which directly implicate vasopressinergic system dysfunction in human psychiatric conditions. The goal of this review will be to provide a synthesis of this evidence into specific rationale supporting the targeting of individual AVP receptor subtypes for CNS drug development.
ARGININE VASOPRESSIN BIOLOGY
AVP is a nonapeptide (Cys 1 -Tyr 2 -Phe 3 -Gln 4 -Asn 5 -Cys 6 -Pro 7 -Arg 8 -Gly 9 ) with a cyclic structure formed through a disulphide bridge between two cysteine residues. AVP is generated through enzymatic processing of a propeptide encoded for by the preproAVP (ppAVP) gene, which is localized genomically to the short arm of human chromosome 20 (20p13) [14] . The ppAVP peptide is 164 amino acids in length and is cleaved by endopeptidases into four separate polypeptides: biologically active AVP (20) (21) (22) (23) (24) (25) (26) (27) (28) , a signal peptide (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) , the putative carrier protein neurophysin 2 , and a carboxy-terminal glycoprotein referred to as copeptin [15] . Processing of ppAVP is believed to occur during axonal transport of the peptide along the secretory pathway, which extends from the endoplasmic reticulum (ER) to the secretory granules (SC) [16] . This processing (glycosylation, proteolysis, amidation) occurs in distinct compartments and contributes to the ultimate separation and reshaping of its three peptide products [17] . In synaptic terminals, AVP, neurophysin 2 and copeptin products are found in secretory vesicles and are released following nerve depolarization [18] .
Upon release into extracellular space, AVP is subject to a number of enzymatic and physical pressures that challenge its half-life and functional activity. Following release, AVP has a relatively short half-life (<1 minute) in the CNS [19] . AVP is also subject to N α -acetylation, which results in loss of the peptide's intrinsic peripheral and central activities [20, 21] .
AVP also serves as a precursor peptide for smaller, biologically active fragments, known as metabolites. Processing of the parent peptide AVP (1) (2) (3) (4) (5) (6) (7) (8) (9) into smaller fragments is not random, but occurs along a pathway of stepwise cleavages, resulting in the preferential formation of several linear peptides (e.g. AVP (4) (5) (6) (7) (8) (9) , AVP (4) (5) (6) (7) (8) , AVP (5) (6) (7) (8) (9) , AVP (5) (6) (7) (8) ) [22] . The generation of these C-terminal AVP metabolites has been demonstrated in synaptosomal membrane preparations and detected throughout the CNS in vivo [22, 23] . These metabolites lack peripheral endocrine activity, show regional differences in extracellular concentrations within the CNS, and, in most cases, exhibit more potent mnemonic and selective behavioral activity than the parent peptide AVP (1) (2) (3) (4) (5) (6) (7) (8) (9) [24, 25] .
AVP and OT share seven of their nine amino acids in common and are generally thought to have resulted from a gene duplication/inversion event that, from an evolutionary perspective, predates the divergence of invertebrates and vertebrates [26] . AVP and OT have different endocrine effects on peripheral systems, yet these peptides exert influence over similar functions in the CNS, often with oppositional effects to one another [27] . This functional overlap of vasopressinergic and oxytocinergic systems has led some to refer to these neuropeptides as 'ying-yang' neurohormones [28] . Although the significance of this overlap to CNS function has been demonstrated, and may serve some relevance to understanding the clinical implications of central vasopressinergic disturbances addressed in this review, it will not be addressed as a subject here. nergic systems, can be defined based on differences in anatomical sites of action and physiological function.
The peripheral vasopressinergic system refers to those sites of action and physiological functions for AVP released into peripheral circulation from neurosecretory nerve terminals in the posterior pituitary that originate in the supraoptic nucleus (SON) of the hypothalamus. AVP released from the posterior pituitary gives rise to its classic endocrine functions: 1) regulation of free water absorption and urine output in the kidneys; 2) constriction of vascular smooth muscle; 3) increased glycolysis, gluconeogenesis, esterification, and oxidation of free fatty acids in the liver; 4) aggregation of blood platelets [29, 30] .
The central vasopressinergic system refers to the sites of synthesis and release within the CNS, where AVP acts as a neuromodulator/neurotransmitter regulating an array of CNS-mediated functions (e.g. learning and memory, neuroendocrine reactivity, social behaviors, circadian rhythmicity, thermoregulation, and autonomic function). This central vasopressinergic system is both anatomically and functionally separate from the peripheral vasopressinergic system, a partitioning of AVP effects enforced physiologically by the general impermeability of the blood brain barrier (BBB) to AVP [31, 32] . The central vasopressinergic system has been most extensively studied in the CNS of rodents, particularly rats. Unless otherwise noted, all neuroanatomical descriptions provided herein are taken from studies in these animals.
Neuroanatomy of the Central Vasopressinergic System
In the CNS, AVP is synthesized by two types of neurons, magnocellular neurosecretory cells (MNCs) and parvocellular neurosecretory cells (PNCs) [33, 34] .
Vasopressinergic MNCs are restricted to hypothalamic nuclei, namely the SON, paraventricular nucleus (PVN), nucleus circularis, and accessory nuclei. MNCs of the hypothalamic SON and PVN are the principle source of AVP released into peripheral circulation, just as Bargmann and Scharrer had postulated over 50 years ago [35] . These cell types give rise to what is known as the hypothalamicneurohypophyseal system, and are perhaps the most studied of all neuroendocrine cell types. Vasopressinergic MNCs of these nuclei, primarily the SON, synthesize, transport, and release AVP upon depolarization from axon terminals in the posterior lobe of the pituitary. See Fig. (1A) . Release is triggered by somatodendritic action potentials arising from the SON in response to a variety of stimuli including: changes in plasma osmolality, depletion of extracellular fluid volume, decreases in blood pressure, and stressors such as fever, restraint and pain [36, 37] .
Vasopressinergic PNCs of the PVN are located in the medial, lateral, and dorsal subdivisions. These fibers can be divided into those that form projections to the median eminence, and those that form extra-hypothalamic projections descending towards autonomic centers of the brainstem and spinal cord. See Fig. (1B) . The anatomical organization of the PVN makes it a critical nexus for the integration of circuits mediating neuroendocrine and autonomic function [38] . The medial division of the PVN is the source of vasopressinergic projections to the external zone of the median eminence, where AVP is released into the portal circulation of the anterior pituitary (adenohypophysis). Acting through vasopressinergic receptors expressed on adenohypophyseal corticotrophs, primarily of the V 3 R (V 1b ) subtype, AVP acts synergistically with corticotropin releasing factor (CRF) to stimulate adrenocorticotropin hormone (ACTH) release from the anterior pituitary into the peripheral circulation. [39] Vasopressinergic neurons of the medial, lateral, and dorsal PVN give rise to projections descending into autonomic centers within the hindbrain and spinal cord, and are distinct from those projecting to the median eminence [38, [40] [41] [42] [43] . These descending fibers include projection areas in the parabrachial nucleus (PB), dorsal motor nucleus of the vagus and nucleus of the tractus solitarius (collectively termed the dorsal vagal complex, or DVC), nucleus ambiguus (Amb), and the intermediolateral column of the spinal cord (IML) [40] . As many as 40% of descending parvocellular projections from the PVN are estimated to be vasopressinergic [44] . Together with the absence of other descending vasopressinergic fibers to the spinal cord from other nuclei, this indicates that the PVN is the primary source of AVP innervation for spinal sites [33, 40, 45] . The importance of the PVN to homeostatic regulation of autonomic functions suggests that these projections are responsible for vasopressinergic control of autonomic activity and nociception at the spinal level.
Vasopressinergic cells make up a significant percentage (10-30%) of neurons in the SCN, and innervate both intra-SCN and extra-SCN sites [46] [47] [48] [49] . Neurons of the SCN are responsible for the circadian pacemaker activity in mammals, generating endogenous circadian rhythmicity and influencing effector systems (behavioral, neuroendocrine, parasympathetic and sympathetic) through its numerous efferent pathways [50] . Vasopressinergic efferents from the SCN target the medial preoptic area (MPA), periventricular area of the PVN (Pe), paraventricular nucleus of the thalamus (PV), and dorsomedial hypothalamic nucleus (DM) [51] [52] [53] [54] . See Fig. (1C) . Although the functional role of these circuits has not been elucidated, it is reasonable to suggest that vasopressinergic output from the SCN participates in the synchronization of physiology (behavior, neuroendocrine function, parasympathetic and sympathetic functions) of an organism to daily changes in activity. AVP synthesis has been described in other CNS sites, many of which are revealed only following treatment with the axonal transport blocker colchicine [55] . The most prominent of these extrahypothalamic sites are the intermediate and medial subdivisions of the bed nucleus of the stria terminalis (BST), and the anterior and posteriodorsal subdivisions of the medial amygdaloid nucleus (MeA), which provide a large percentage of overall vasopressinergic innervation throughout the CNS [55] [56] [57] . Expression of AVP in these two structures is dependent on sex steroids, and gonadec-tomy results in a complete elimination of AVP expression among cells of BST and MeA [58] . These sites also are sex-ually dimorphic with males exhibiting more AVP immuno-reactive neurons relative to females [59] . The projection areas for vasopressinergic neurons of the BST include the lateral habenular nucleus (LH), central grey (CG), dorsal raphe nucleus (DR), A6 cell group (locus coeruleus or LC), lateral septum (LS), vertical diagonal band of broca (MDBB), and the olfactory tubercle (Tu) [57] . See Fig. (1D) . Vasopressinergic efferents from the MeA project to the LS by the ventral amygdalofugal pathway and to the ventral hippocampus through the amygdalohippocampal transition zone [60] . See Fig. (1E) .
Other areas of AVP synthesis have been suggested by in situ localization of mRNA or immunohistochemistry. A dense network of AVP immunoreactive cells has also been observed in the LC, but the exact source of AVP in this region remains controversial [61] . It has been suggested that AVP content in the LC originates from other sites because vasopressinergic immunoreactivity is not observed in this area following colchicine pretreatment [56, 62] . Additionally, lesions of the LC do not appear to affect AVP immunoreactivity observed in other regions of the CNS [62, 63] . In situ hybridization studies have identified the expression of ppAVP mRNA in a number of additional sites throughout the CNS including the choroid plexus, horizontal limb of the diagonal band of Broca, dorsal tegmental area, parabrachial nucleus, hippocampus (CA1, CA3), and dentate gyrus [64] [65] [66] . Evidence regarding the existence of these additional sites of AVP synthesis, however, remains controversial, and their functional significance remains to be determined.
AVP Receptor Subtypes: Function and Distribution in the CNS
The biological activity of AVP is mediated through a phylogenetically related family of guanine nucleotidebinding (G-protein) coupled receptors. This family features four subtypes defined on the basis of differences in pharmacology and tissue distribution. (See Table 1 for summary) The known subtypes are V 1 R, V 2 R, and V 3 R, and also includes the OT receptor (OTR), which exhibits a low nanomolar affinity for AVP. Two additional receptors have been identified that exhibit affinity for, and are functionally responsive to AVP, but are not related by sequence to the known family of AVP receptors. These are the dual angiotensin/AVP receptor (AT II /AVP) and calcium mobilization receptor 1 (VACM-1).
V 1 R
V 1 R is often referred to as the vascular AVP receptor, owing to its strong expression in smooth muscle cells of the cardiovascular system. V 1 R is widely expressed among peripheral tissues (liver, vascular smooth muscle, kidney, spleen, testis) and structures of the CNS [67] . Binding of AVP to V 1 R activates a number of signal transduction pathways via G q coupling to phospholipase C (PLC), A2 or D [68, 69] . AVP binding leads the rapid hydrolysis of phosphatidyl inositol-4, 5-bisphosphate (PIP 2 ) into inositol-1, 4, 5-triphosphate (IP 3 ) and diacylglyceraldehyde (DAG), mobilization of intracellular calcium, activation of a variety of kinases including p42/p44 mitogen activated protein kinase, calcium/calmodulin-dependent kinase II, protein kinase C, as well as cell acidification through activation of Na + /H + exchange [70] [71] [72] . Differences in intracellular signaling pathways were originally the basis of distinction between the vascular and renal AVP receptors. Similarities in signaling pathways with α 1 -adrenergic and H 1 -histamine receptors led Michell et al. to propose the V 1 designation for vascular receptor subtype, and the V2 designation for the renal AVP receptor [73] .
In situ hybridization studies indicate a extensive distribution of V 1 R throughout the CNS [74, 75] . Sites of mRNA expression include the hippocampal formation, central amygdala, dorsolateral the septum, lateral hypothalamus, SCN, ventromedial, dorsomedial, and arcuate nuclei of the hypothalamus, NST, cerebellum, spinal nucleus of the trigeminal tract, reticular formation, inferior olivary nucleus, and choroid plexus [76] . Radioligand binding studies with the V 1 R-selective antagonist [ 3 H]SR-49059 have been generally consistent with these results, and reveal intense specific labelling in the LS, fundus striatum, hypothalamic stigmoid nucleus and the area postrema-nucleus of the solitary tract complex [77] . To date, however, detailed descriptions of V 1 R immunoreactivity throughout the CNS have not been reported.
V 2 R
The principle site of V 2 R receptor expression is the kidney; it has been subsequently referred to as the renal vasopressin receptor. In the kidney V 2 R is selectively expressed on the basolateral membrane of the distal collecting tubules of where is plays a critical role in mediating AVP inhibition of diuresis in the nephrons. The primary biological endpoint of AVP signaling through V 2 R in the kidney is the insertion of the aquaporin-2 (AQP-2) water channels into the luminal surface of cells along the renal collecting tubule [78] . AQP-2 channel insertion increases water re-absorption by the kidneys, which underlies the antidiuretic effect of peripherally released AVP [79] . Following the cloning of V 2 R, it was demonstrated conclusively that mutations in the V 2 R gene were responsible for congenital nephrogenic diabetes insipidus, an X-linked disorder where patients fail to respond to AVP [80] . V 2 R is the only receptor in the AVP/OT family that preferentially signals via G s and cAMP. Upon AVP binding, V 2 R couples to adenylyl cyclase (AC) via the cholera toxinsensitive G s protein. Coupling triggers activation of AC, increased catalysis of ATP into cAMP, and the subsequent activation of protein kinase substrates such as protein kinase A (PKA). Prior to the cloning of V 2 R, the receptor was distinguished from the cardiovascular AVP receptor (V 1 R) based this differences in intracellular signaling pathways.
Our understanding of V 2 R expression in CNS is limited by the absence of localization studies. This is unusual considering that much of the early work with AVP analogs and behavior focused on V 2 R-selective peptides. Despite this, several studies have indicated limited expression of V 2 R among structures the CNS. V 2 R mRNA has been detected by RT-PCR in the hippocampus of adult rats [81] . Strong expression of V 2 R is also observed in the epithelial cells and vascular endothelial cells of the choroid plexus [82] . • V1a or V1A
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receptor originates from similarities in intracellular signaling with the V1-vascular receptor, which initially led to the subtype designations V 1a (vascular) and V 1b (pituitary) often seen today [83] . Following the molecular cloning of the pituitary receptor, additional differences in binding characteristics and intracellular signaling pathways were elucidated, which added further distinction between these two receptors and the revised designation V 3 R [84, 85] .
Similar to V 1 R, the principle pathway of intracellular signaling for V 3 R occurs via G q/11 coupling to PLC isoforms. AVP binding leads to rapid hydrolysis of phosphatidyl inositol-4, 5-bisphosphate (PIP 2 ) by β-isoforms of phospholipase C (PLC) into inositol-1, 4, 5-triphosphate (IP 3 ) and diacylglyceralde-hyde (DAG) [86] . Increases in IP 3 turnover result in a transient mobilization of calcium into the cytoplasm from IP 3 -sensitive stores located primarily in the endoplasmic reticulum. Depending on the level of expression, however, V 3 R can also couple via G q/11 alone, or in combination with G i , adding further distinction from V 1 R [86, 87] . For additional information on the V 3 R receptor, see review by Rene et al. [88] .
The presence of V 3 R mRNA has been described in a number of peripheral tissues (pituitary, kidney, pancreas, adrenal medulla), but the functional significance of these sites of expression remains unclear [84, 89] . Immunolocalization studies indicate that V 3 R is widely expressed in the rodent CNS [90] . The expression of V 3 R protein in neuronal and fiber systems can be functionally divided into two groups [90] . The first includes those structures where V 3 R immunoreactivity is observed exclusively in fiber systems. These are found in areas devoid of the BBB (subfornical organ, organum vasculosum laminae, median eminence) or in close proximity to the cerebroventricular system (periventricular thalamic nuclei, hypothalamic nuclei, medial habenula, mammilary bodies). The second group features V 3 R expression that is restricted to cell bodies, and includes the periform cortex, olfactory tubercle, hippocampus, lateral septum, cingulate cortex, frontal cortex, and cerebellum. V 3 R expression in cell bodies was also detected in the caudate putamen where AVP binding has not been previously demonstrated [90] .
OTR
OTR is expressed both in the periphery (uterus, mammary glands) and throughout the CNS. Although OTR has a nanomolar affinity (16 nM) for AVP, AVP receptor subtypes have only a weak affinity for oxytocin. OTR is widely expressed throughout the CNS [91] . Although the functional relevance of OTR to central vasopressinergic function is implicit, the contributions of OTR to central vasopressinergic activity should be the focus of a separate treatise, and will not be covered as part of this review. The reader is referred to a review by Gimpl and Fahrenholz for additional information on the central oxytocinergic system [92] .
Other AVP Receptors
Two atypical receptors have also been identified that exhibit affinity for, and mediate intracellular responses to, AVP. These include the dual angiotensin/AVP receptor (AT II / AVP) and calcium mobilization receptor 1 (VACM-1). Interestingly, the sequences for both receptors fail to show similarities with the known family of AVP receptors, and the receptors are both ubiquitously expressed across peripheral tissues and structures of the CNS [93] . AT II /AVP exhibits equal affinity for both angiotensin and AVP and is signals through AC [94] . VACM-1 is a recently discovered member of the cullin gene family of receptors, which participate in the regulation of the cell cycle [95] . VACM-1 has affinity for AVP (K d = 2 nM), and can discriminate between AVP and OT, but not between V 1 R and V 2 R ligands [96, 97] . The functional significance, if any, for either receptor in mediating effects of AVP in vivo remains to be determined.
AVP Effects on Behavior
Learning and Memory
As described above, the importance of AVP to learning and memory was first established with the observations of David de Wied almost 40 years ago. In this landmark report, de Wied described that removal of the posterior and intermediate lobes of the pituitary facilitated extinction of shuttle box learning in rats, (animals that also suffered from mild diabetes insipidus) [7] . In turn, de Wied demonstrated that the extinction of conditioned avoidance behavior observed in these animals could be normalized by administration of a crude pituitary extract of AVP (pitressin) or long acting preparation of vasopressin [98] . In the years since de Wied's observations, a clear role for the central vasopressinergic system has been demonstrated for AVP in various paradigms of learning and memory.
AVP has effects on active avoidance learning. Systemic administration of AVP delays extinction of the pole-jump avoidance response in rats, while central administration of the AVP receptor antagonist [1-deaminopenicillamine-2-(O-methyl)tyrosine]AVP (dPTyr(Me)AVP) produced an opposite reaction, the facilitation of extinction [99] . Memory retrieval, measured by retention-test performance on a onetrial step-through inhibitory avoidance task, is enhanced by pre-treatment with lysine vasopressin (LVP), and inhibited by the AVP receptor antagonist d(CH 2 ) 5 Tyr(Me)AVP [100] .
AVP has a role in the maintenance of conditioned taste aversion (CTA). In the CTA paradigm, animals learn to associate a novel taste (conditioned stimulus) with nausea (unconditioned stimulus), and as a consequence avoid drinking fluid with this specific taste. Typically, animals are trained to prefer a sweetened solution (saccharin) prior to pairing it with an aversive additive (LiCl). Administration of the AVP analog desglycinamide-lysine vasopressin (DGLVP) was shown to increase resistance to extinction (decline in the frequency or intensity) of a CTA [101] . Studies in Brattleboro rats, which are deficient in AVP synthesis, have demonstrated that AVP is required for the expression of CTA [102] . Maintenance of CTA behavior in rats is positively correlated with increased AVP content in the PVN and MeA [103] . Maintenance of CTA behavior, which declines with aging, can be improved in older animals by treatment with LVP [104] .
The central vasopressinergic system is also implicated in appetitively-motivated learning. Vawter et al. demonstrated that AVP pre-training administration of desglycinamide-AVP (DGAVP) produced dose dependent facilitation of learning and both reference and working memory in the hole-board search task [105] . AVP has also demonstrated facilitatory effects on appetitive learning in a water-finding search task [106] . In the brightness discrimination test, another food motivated paradigm, 1-desamino-8-D-AVP (DDAVP) facilitated acquisition and lessened the reversal of learning [107] .
Some have argued that enhancement of cognitive functions such as learning by AVP is not mediated through direct actions on CNS activity, but indirectly through changes in the motivational and arousal processes of animals [108, 109] . Increases in arousal state were postulated to be the consequences of the aversive effects of peripherally administered AVP [110, 111] . The exact contribution, or contamination, of these results by performance factors such as arousal remain to be determined, but this controversy helped to turn the field more towards the evaluation of AVP effects on social memory, which is arguably a more natural test of memory in rodents [112] .
It has been widely demonstrated in a variety of rodent models that AVP has a facilitatory influence on social recognition memory. Social memory is commonly assessed by evaluating the tendency of rodents to investigate more intensely unfamiliar conspecifics than familiar ones [113] .
These studies usually involve examining the duration of time an adult rat investigates (sniffing, nosing, following, and grooming) a juvenile animal presented to it. Increases in social memory, or recognition, are reflected by decreases in time spent investigating the same conspecific upon subsequent exposures. AVP administered to an adult shortly after first exposure to a juvenile conspecific decreases the amount of time the animal spends investigating it upon second exposure [114] . The facilitatory effect of AVP on social recognition can be blocked by administration of dPTyr(Me)AVP [115] . Microinfusion of V 1 R antisense oligonucleotides into the septum diminishes recognition of conspecifics [116] . Administration of dPTyr(Me)AVP or antiserum to AVP, prior to the initial presentation of a conspecific, impairs recognition of the same animal upon second exposure, supporting a role for endogenous AVP in normal social memory processes [117] [118] [119] .
The importance of AVP to social behaviors has been further established through studies in other rodent species such as hamsters (Mesocricetus) and voles (Microtus). In Syrian hamsters (Mesocricetus auratus), AVP has been shown to increase flank marking and aggressive behavior, two behaviors which are important to the establishment and maintenance of dominant/subordinate relationships in these animals [120, 121] . The importance of the central vasopressinergic system to social behaviors (affiliation, paternal care, and pair bond formation) has also been established through studies in voles (for review see Wang et al. [122] ). AVP studies in voles has featured some of the more provocative work in the field by Insel and Young, who have helped to establish the importance of central vasopressinergic function to differences in affiliative behavior and social attachment between monogamous and non-monogamous species of prairie voles [123, 124] .
AVP Effects on Neuroendocrine (HPA) Function
The effects of AVP on anterior pituitary function can be defined as an altogether distinct vasopressinergic system (hypothalamic-adenohypophyseal AVP system), but for the purposes of this review they will be referred to as an extension of the central vasopressinergic system. As described above, PVCs of the PVN give rise to vasopressinergic projections that terminate in the external zone of the median eminence [125] . From these terminals, AVP released into the portal circulation of the anterior pituitary [125] . Although AVP is considered to be a weak secretagogue of ACTH alone, it does act synergistically with CRF at the level of corticotrophs to potentiate ACTH release from the 'rapidturnover' pool [125, 126] . In the years surrounding the historic synthesis of AVP by Vincent du Vigneaud, this peptide had actually been postulated to be the elusive CRF responsible for ACTH release from the anterior pituitary [88, 127, 128] . Although evidence had supported an argument for a pivotal role of AVP in the regulation of ACTH release, it was conclusively demonstrated in 1981 by Vale et al. that CRF was an altogether different peptide [129] . Despite this, evidence still clearly indicates the importance of AVP to the regulation of anterior pituitary responsiveness. HPA activation in response to a variety of stimuli (e.g. immobilization stress, novelty, insulin, high doses of colchicine) leads to the depletion of AVP and CRF in the median eminence [130] . Co-administration of AVP and CRF produces as high as a 30-fold greater ACTH response than CRF alone [131] .
Expression of CRF and AVP in the hypothalamus is differentially responsive to circulating glucocorticoids, and evidence suggests these neuropeptides play separate roles in maintaining the responsiveness of the HPA between basal and challenged (stressful) states [132] . Whereas CRF is generally thought to provide stimulatory drive on the HPA axis, AVP can be thought of as providing situation-specific drive by preserving corticotroph responsiveness in the face of the feedback inhibition from increased levels of circulating corticosteroids [88] . Further detail on this is described below.
Central Effects of AVP
Antipyresis
A role for AVP as an endogenous antipyretic peptide has been widely demonstrated. Endogenous release of AVP in the ventral septal area (VSA) is commensurate with fever, and is negatively correlated with febrile changes in body temperature [133] . Administration of AVP receptor antagonists, or antisera to AVP, potentiates hyperthermia induced by a variety of pyrogens (e.g. prostaglandin E1, ) [133, 134] . Brattleboro rats, which fail to produce functional AVP, fail to exhibit enhanced fever responses [135] . Evidence indicates that AVP likely acts on neurons of the VSA to mediate this thermoregulatory response during fever [134] . A role for AVP in febrile responses to immunogenic agents (e.g. bacterial endotoxin, interleukin-1) appears to be sexually dimorphic in rodents, with a more prominent role for AVP as an endogenous antipyretic in male rats [136] . To date, however, evidence does not support a role for endogenous AVP in the regulation of normal, non-febrile states. For additional reading on AVP and fever regulation, please see a review by Pittman et al. [137] .
Central Control of Cardiovascular Function: AVP is a Powerful
Numerous studies have demonstrated the importance of the central vasopressinergic system to regulation of blood pressure and heart rate [138] . Intracerebroventricular (i.c.v.) and intrathecal (i.t.) administration of AVP, as well as in situ microinjection, all produce increases in blood pressure and heart rate [139] [140] [141] [142] [143] . AVP exerts influence on cardiovascular function through actions on sympathetic outflow from autonomic efferent nerves of the CNS to the heart and vasculature [138] . It should be noted that centrally-mediated effects of AVP on cardiovascular function involve wellrecognized interactions with behavioral substrates, such as exercise. Evidence indicates that vasopressinergic innervation of the NTS is important to the regulation of reflex bradycardia and the modulation of heart rate control during exercise [144] . Increases in AVP content in the NTS is commensurate with exercise and potentiation of the tachycardia response [145] . Exercise-induced increases in tachycardia could be blunted with administration of the V 1 R antagonist d(CH 2 ) 5 Tyr(Me) AVP into the NTS [145] .
AVP IN HUMAN CNS DISORDERS Depressive Disorders
Gold et al. were among the first to hypothesize a role for vasopressinergic disturbances in the pathophysiology of affective disorders in humans, based on evidence from animal studies indicating the ability of AVP to influence the symptom complex of affective illness: memory, pain sensitivity, synchronization of biological rhythms, the timing and quality of R.E.M. sleep, regulation of fluid and electrolyte homeostasis, and monaminergic systems in the CNS [146] .
Clinical observations support a positive correlation between plasma levels of AVP and the presentation of depression and the severity of depressive symptomology [147] . Elevated plasma levels of AVP are observed in patients with depression [147, 148] . CSF levels of AVP peptide in depressed patients are decreased with antidepressant treatments (fluoxetine), as are mRNA levels in the hypothalamus (paroxetine) [149, 150] . Imipramine produces significant decreases in responses to peak ACTH by AVP [151] . Vasopressinergic responsiveness to antidepressants, however, appears to differ with class of compounds, as amitryptiline does not produce similar elevations in CSF AVP levels [152] . Increases in plasma AVP levels also show a positive correlation with a blunting of the thyrotropin (TSH) response to thyrotropin-releasing hormone (TRH) in depressed patients [153] . Blunting of the TSH response has been used to predict the likelihood that patients will respond to antidepressant treatment [154] .
It is important to note that discrepancies in the clinical associations between CSF/plasma AVP levels and depression have been reported. Gjerris et al. reported CSF levels of AVP were significantly lower in patients with either endogenous or non-endogenous depression [155] . Although an increase in CSF AVP levels were reported in manic patients, no changes were reported for those with depression [156] .
The role of AVP in mediating ACTH release from anterior pituitary, particularly during stress, has been a point of focus for investigators seeking to explain neuroendocrine imbalances frequently observed in depression [157] . Hyperactivity of the HPA axis is one of the most consistent pathological findings in patients with chronic depression, and is hallmarked by increased circulating cortisol levels [158] . Hyperactivity of the HPA is observed in a many as 50% of depressed patients, and can be revealed clinically using the dexamethasone suppression test (DST) [159] . In the DST, patients are challenged with administration of the potent synthetic corticosteroid dexamethasone (DEX), which in normal patients leads to a suppression, via feedback inhibition, of ACTH release from the anterior pituitary, and subsequently a decrease in plasma cortisol levels. Plasma cortisol levels in many depressed patients (Cushing's syndrome excluded), however, cannot be suppressed with DEX administration, and thus said to 'escape' DEX suppression. ACTH release in response to CRF challenge is also blunted in patients with depression, but responsiveness to vasopressinergic challenge is enhanced [160] . Vasopressinergic influence over HPA responsiveness is less sensitive to the negative feedback pressure of increased levels of glucocorticoids, when HPA responsiveness to CRF challenge is suppressed [157] . This shift from CRF to AVP regulation of ACTH release is hallmark of vasopressinergic influence over corticotrophs during responses to stress [161, 162] . It is speculated that hyperactivity of the HPA and DST escape in depressed patients may result from hypersecretion of AVP. Consistent with this, hypercortisolemia in depressed patients is positively correlated with plasma AVP levels [163] . Hypercortisolemia and suicide behavior in patients with major depression is also associated with disturbances in vasopressinergic activity [164] . Examination of post-mortem tissue from patients with depression reveals increases in the number of AVP-immunoreactive neurons in the PVN, the source of AVP released into the adenohypophyseal portal circulation [165, 166] . Moreover, evidence indicates that the shift in CRF/AVP control of HPA reactivity is also related to increased expression of pituitary AVP receptors, specifically the V 3 R subtype [157] .
Evidence from animal studies has also helped to confirm the relevance of central vasopressinergic system disturbances to depressive symptomology observed in humans. For example, abnormalities in central vasopressinergic system function feature prominently in the depressive endophenotype of rats selectively bred for extremes in anxiety behavior, referred to as either High (HAB) or Low (LAB) Anxiety Behavior animals. Under basal conditions, or following exposure to mild stressors, expression of AVP mRNA and central release of AVP peptide is significantly higher in the PVN of HAB animals than in LAB animals [167] . In addition to increased anxiety-like behavior, HAB animals also show a preference for passive stress-coping behavior, indicative of depressive-like behavior (see review [168] ). As seen in patients with depression, HAB animals exhibit hyperreactivity of the HPA axis following exposure to chronic stress [169] . HAB animals also demonstrate escape from DEX suppression of ACTH release when challenged with CRF the combined DEX/CRF challenge test, consistent with the pathological finding in humans [170] . In the forced swim test, HAB animals show decreased latency to float, increased immobility, and less struggling than LAB rats [171] . In these animals, both depressive-like behaviors and enhanced AVP expression in the PVN are normalized by treatment with the antidepressant paroxetine [172] .
Disturbances in circadian rhythms are frequently observed in patients with depression [173, 174] . Pharmacological modulation of chronobiological substrates, the SCN in particular, has been proposed as a novel target for the development of antidepressant compounds [175] . As described earlier, the role of AVP in regulating circadian rhythmicity and output from the SCN is well established. Consequently this suggests that disturbances in vasopressinergic activity in this hypothalamic structure may participate in the circadian desynchronization observed in psychiatric disorders such as depression. In support of this, examination of postmortem samples from patients with major depression indicate that AVP immunoreactive cells in the SCN are abnormally increased compared to unaffected controls [176] . Increased synthesis and release of AVP was also found in the SCN of rats subjected to the stress of forced swimming, an paradigm commonly used to model depressive behavior animals [177] .
Anxiety Disorders
Anxiety disorders are characterized by persistent feelings of apprehension, tension, or uneasiness, as well as associated physical symptoms (e.g. dizziness, lightheadedness, chest / abdominal pain, nausea, increased heart rates, or diarrhea). In contrast to mood disorders, comparatively fewer clinical associations between vasopressinergic function and anxiety disorders have been studied in humans. The neuroanatomical distribution of vasopressinergic fibers and AVP receptors throughout the CNS already suggest, a priori, the relevance of AVP to the regulation of key neuroendocrine (e.g. HPA), limbic (e.g. LS, MeA, PVN, BST), and autonomic substrates (e.g. PB, DVC, Amb, IML) underlying behavioral responses to stress, in particular those circuits relevant to fear/anxiety behavior. Studies in animal paradigms used to model anxiety-like behavior support a role for AVP in mediating anxiety behaviors, and suggest the potential involvement of the central vasopressinergic system dysfunction in the pathophysiology of anxiety disorders in humans.
An anxiogenic role for AVP is also suggested by results of studies performed in normal animals. Increases in the percentage of time spent in the open arms of the EPM are observed following central administration of AVP suggesting an anxiogenic-like effect for this peptide [178] . Central administration of different AVP receptor antagonists produce anxiolytic-like responses [179] .
HAB and LAB rats have provided investigators with the opportunity to examine trait anxiety, and evidence from studies with these animals collectively suggest a critical role for the central vasopressinergic system in anxiety behavior [180] . HAB animals display inherent increases in central AVP mRNA expression, peptide release, and receptor binding within the hypothalamus [167] . HAB animals exhibit enhanced anxiety-like behavior in several models of anxiety-like behavior, including the elevated plus maze (EPM), social defeat paradigm, and modified hole board test [180, 181] . Anxiety-like behaviors in HAB animals are reduced by treatment with both AVP receptor antagonists and the clinical effective anxiolytics diazepam and paroxetine [167, 172, 182] .
Clinically effective anxiolytics such as paroxetine (Paxil), buspirone (Buspar), and chlordiazepoxide (Librium) have been shown to decrease ppAVP mRNA expression in the rat CNS [150] . This suggests that different classes of compounds, working through distinct molecular targets to produce anxiolysis, share in common the ability to significantly down-regulate mRNA encoding the ppAVP peptide in the amygdala of rats. This suggests a shared mechanism of action (MOA) involving the central vasopressinergic system. Disturbances in central vasopressinergic system have also been implicated in obsessive-compulsive disorder (OCD). OCD is a subtype of anxiety disorders characterized by sudden, recurrent thoughts or images (obsessions) that intrude into consciousness driving stereotyped acts (compulsions) that the person feels compelled to perform [183] . Associations between vasopressinergic abnormalities and OCD have been observed in both adult and pediatric patients with this disorder [184, 185] . Elevated levels of both plasma and CSF AVP have been specifically noted, as well as exaggerated vasopressinergic responses to hypertonic challenge [184, 185] . Long-term (~19 months) treatment with the tricyclic antidepressant clomipramine (Anafranil) produced significantly decreased CSF levels of AVP in children and adolescents with OCD [186] . In rodents, stereotyped behaviors, such as repetitive grooming, have been proposed as ethological correlates to OCD in animals [187] . Microinjections of AVP into the CNS of hamsters produce intense stereotypic grooming and flank marking behavior in hamsters [188, 189] . These effects are blocked by vasopressin receptor antagonists and/or drugs used clinically for the treatment of OCD [190, 191] . Similar effects on grooming behaviors have been observed with other drugs (clomipramine, desipramine, fluoxetine, fenfluramine, and sertraline) in the canine acral lick model of OCD [192] .
Together, the evidence strongly suggests an anxiogenic role for AVP in the CNS, and suggests that central antagonism of the vasopressinergic system may offer a novel mechanism of action to achieve therapeutically relevant anxiolysis.
Cognitive Disorders
Over thirty small clinical trials have sought to assess the effects of AVP, or synthetic peptide analogs, on memory in humans.(see review [13] ) The majority of these studies have focused on healthy subjects and, in general, report improvements in memory with intranasal administration of AVP, DDAVP, or DGAVP. Examination of these results suggests that AVP is more closely associated with declarative memory, rather than procedural memory [13] .
Animal studies have demonstrated the ability of AVP to reverse impairments in learned behaviors (retrograde amnesia) induced by a variety of adverse stimuli including electroconvulsive shock, pentylenetetrazole, puromycin, CO 2 inhalation or disruption of circadian rhythmicity [193] . Izquierdo et al. demonstrated that pretest administration of AVP can reverse the amnesic effect of either beta-endorphin challenge or electroconvulsive shock on learned avoidance behavior in rats [194] . In mice, pretest administration of LVP reverses amnesia for a passive avoidance response induced by anisomycin [195] .
Decline of cognitive functions such learning and memory are commonly observed with aging, as are disturbances in normal vasopressinergic activity within the CNS. AVP content in the hippocampus and hypothalamus (SOC and PVN) decreases with age [196, 197] . In elderly patients, the vasopressin analog DDAVP improves memory [198] . Intranasal administration of DDAVP also produced modest improvements in memory in healthy adult volunteers [199] . Both memory comparison time and perceptual-motor time in short-term memory (STM), and retrieval time in long-term memory (LTM) were improved with AVP administration in young and old patients [200] . Patients with degenerative dementia have significantly lower CSF levels of AVP than controls [156, 201] .
Post-mortem examination of brains from patients with Alzheimer's Disease (AD) reveals decreased AVP content in a number of CNS regions including the: hippocampus, nucleus accumbens, and globus pallidus interna [202] .
Increases in hypothalamic AVP immunoreactivity and concentrations have also been detected in AD [203, 204] . Studies also reveal reduced levels of AVP in the CSF of AD patients [205] . As AD is associated with disruptions in the oscillating diurnal and vasopressinergic activity of SCN neurons observed in younger populations, changes in SCN vasopressinergic activity may participate in disturbances of the sleep-wake cycle and endocrine rhythms that occur in this condition [197, [206] [207] [208] . AD is also hallmarked by alterations in amyloid processing [209] . AVP also appears to influence amyloid processing events in vitro. In NRK-49F cells AVP produces dose-dependent increases in amyloidprecursor protein (APP) secretion [210] . The shifting of APP processing towards non-amyloidogenic derivatives implied by these studies has led some to suggest an involvement of AVP in altered amyloid metabolism, which could be of therapeutic interest for the treatment of AD [211] . Consistent with this line of thought, rats infused with β-amyloid (1-40) show evidence of learning and memory impairments in the Morris water maze that can be prevented by co-administration with the AVP (4) (5) (6) (7) (8) (9) analog NC-1900 [212] . Compounds that inhibit peptidases which degrade AVP and other mnemonic neuropeptides, including the prolyl endopeptidase (PEP) inhibitor JTP-4819, have been proposed as a treatment of AD [213] . JTP-4819 exhibits anti-amnesic properties in a variety of animal models [213] [214] [215] . It is hypothesized that JTP-4819 ameliorates impairments in memory and cholinergic function by inhibiting the degradation of neuropeptides such as AVP [215] .
To date, however, clinical trials have failed to demonstrate efficacy of AVP analogs in the treatment of AD. Once daily administration (intranasal) of the AVP analog DGAVP failed to produce improvements in clinical rating scales or psychometric tests in a trial of 115 patients with mild dementia, probable Alzheimer's type [216] . In a trial involving 14 AD patients, intranasal DDAVP also failed to demonstrate clinical significance on interpersonal subscales of the Sandoz Clinical Assessment Geriatric (SCAG) [217] .
Psychotic Disorders
Evidence of pathological associations between plasma or CSF levels and schizophrenia has been contradictory. Abnormal increases in plasma AVP concentration have been observed in schizophrenic populations [218, 219] . High levels of plasma AVP relative to sodium concentration, a common feature to the syndrome of inappropriate secretion of antidiuretic hormone (SIADH), has been reported in schizophrenic patients lead some to postulate the potential involvement of AVP in the pathophysiology of schizophrenia [220] [221] [222] . Transient psychotic exacerbations in schizophrenic patients, induced by psychotomimetic (methylphenidate) challenge, is positively associated with increased plasma levels of AVP [223] . Some clinical studies have failed to note any differences in AVP levels between controls and schizophrenics [224] . Decreased levels of AVP have also been noted. Mean levels of the AVP carrier protein neurophysin 2 were found to be lower in the CSF of schizophrenics compared with controls [225] . Postmortem analysis, Frederiksen et al. reported a significant reduction of AVP concentration in the temporal cortex of patients with schizophrenia [226] .
Animal studies suggest a potential role for AVP in the regulation of CNS activity associated with schizophrenia in humans. For example, the diverse cognitive and behavioral deficits observed in the AVP-deficient Brattleboro phenotype have been argued by some to exhibit face validity as a putative model for schizophrenia [227] . Brattleboro rats show impairments in memory and cognition reminiscent of those observed in human schizophrenic patients as well as disturbances in sensorimotor gating. Fiefel and Priebe report that both homozygous Brattleboro/HoDi and heterozygous Brattleboro/HeDi rats have significantly higher acoustic startle reflex (ASR) and lower prepulse inhibition (PPI) than observed in Long Evans controls [228] . Diminution of PPI, which is the reduction in startle produced by a prepulse stimulus, is commonly observed in patients with schizophrenia [229] . The PPI deficits of Brattleboro rats are reversed with sub-chronic administration (22 days, s.c.) of the antipsychotic drug haloperidol [228] . Haloperidol and other dopaminergic antipsychotics have been shown to reduce central AVP release. Chlorpromazine and haloperidol have been shown to normalize elevated AVP levels in acute schizophrenic patients [219] .
Despite contradictory evidence of associations from clinical studies, investigators have sought to examine the therapeutic potential of AVP, or analogs of AVP, in schizophrenic patients based on the well-established positive effects on cognition and memory seen with these neuropeptides. Interestingly, pituitary extracts (presumably containing AVP) were used as early as 1952 to treat schizophrenia, with clinical efficacy observed in some, but not all patients studied [230] . More recently, evidence from several clinical trials indicates improvement in schizophrenic symptomology following treatment with AVP analogs. Both open and blind studies using DDAVP in schizophrenic patients, demonstrate significant decreases in negative symptomology, and improvements in memory [231, 232] . These results are consistent with other studies that demonstrated similar improvements with negative symptoms [233] . Electroconvulsive shock therapy, used to treat patients with schizophrenia, produces increases in plasma AVP levels that are observed as long as one week post-shock [234] . The use of AVP agonists as a therapeutic strategy for the treatment of negative symptomology in schizophrenia has also been suggested [235] . The results of clinical studies have not been uniform, or have been hallmarked by modest efficacy. A double blind trial using lysine-8-vasopressin (LVP) in schizophrenics produced selective positive effects on anergy and thought disorder, but lacked efficacy in improving overall function in patients [236] . In longer studies, side effects involving fluid and electrolyte homeostasis have often overshadowed the beneficial effects observed with some analogs [237] .
The association between abnormal AVP secretion in patients with polydipsia and the comorbid presentation of schizophrenia or other psychotic disorders has been actively studied. Although a direct pathophysiological link between polydipsia and psychotic disorders has yet to be defined, psychotic exacerbations in schizophrenic patients are commensurate with increased secretion of AVP, hyponatremia and polydipsia [223] . Water intoxication is commonly coincident with acute psychosis in Schizophrenic patients with hyponatremia. The syndrome of hyponatremia-polydipsia is observed in as many as 5% of patients with chronic schizophrenia [238] .
AVP RECEPTOR SUBTYPES AS THERAPEUTIC TARGETS FOR PSYCHIATRIC DISORDERS
The evidence presented above clearly implicates disturbances in central vasopressinergic activity in the pathophysiology of numerous human psychiatric conditions, in particular depression and anxiety. From the perspective of pharmaceutical development, the opportunities for targeting the AVP receptors of the central vasopressinergic system are implicit in this evidence and warrant closer examination. Historically opportunities for psychotherapeutic development may have been overlooked or underappreciated as drug companies focused efforts towards the exploitation of the peripheral effects of AVP. In the section below, a synthesis of available data is provided and assembled it into specific lines of evidence that rationalize the tractability of each AVP receptor subtype as a molecular target for different psychiatric indications.
V 1 R
To date, V 1 R has not been directly targeted for the development of psychotherapeutics. In contrast, V 1 R has been the focus of extensive efforts by drug companies to develop compounds for the treatment of peripheral indications such as dysmenorrhea, preterm labor, Raynaud's disease, hypertension, congenstive heart failure, brain edema, and motion sickness [239, 240] .
Depressive Disorders
The behavioral pharmacology of peptide-like V 1 Rselective antagonists such as d(CH 2 ) 5 Tyr(Me)AVP have provided evidence suggesting the relevance of this receptor subtype to mood disorders, particularly depression. Local administration of the d(CH 2 ) 5 Tyr(Me)AVP into the septum or amygdala of rats reduces the time spent floating (immobility), and prolonged time spent struggling, when exposed to the stress of forced swimming [241, 242] . This effect is suggestive of an antidepressant-like activity for V 1 R antagonism and emphasizes the importance of the septum and amygdala, where swim stress has been shown to stimulate vasopressinergic activity, to stress-coping behavior in rodents [241, 242] . HAB rats, which exhibit preferences for passive stress-coping strategies suggestive of depressive-like behavior, show reductions in immobility time in the forced swimming paradigm following administration of d(CH 2 ) 5 Tyr (Me)AVP into the PVN [167] . These studies, although limited to discrete brain regions, suggest the potential for V 1 R antagonism as an antidepressant-like mechanism of action.
Anxiety Disorders
The importance of V 1 R to the regulation of behavioral substrates underlying fear and anxiety has been demonstrated by a variety of experimental approaches, and suggest the potential relevance of this subtype to the pathophysiology of anxiety disorders.
Radioligand binding studies indicate that enhanced anxiety behavior is correlated with increased V 1 R binding sites in the CNS. A significantly higher number of V 1 R binding sites are observed in the septum of HAB rats, compared with LAB animals [172] . The septal area is frequently implicated in the control of fear/anxiety behaviors. Increased V 1 R binding in the BNST, another limbic structure integral to the mediation of anxiety behavior, is also correlated with individual differences in anxiety behavior induced by social isolation in rats [243] .
Behavioral pharmacological studies with V 1 R antagonists have confirmed the importance of the V 1 R to anxiety behavior, and suggest the relevance of functional V 1 R antagonism to anxiolysis. When administered by reverse microdialysis into MPOA of rats, the V 1 R-selective antagonist d(CH 2 ) 5 Tyr (Me)AVP produced anxiolytic-like activity in the EPM [244] . Administration of d(CH 2 ) 5 Tyr(Me)AVP directly into the septum of rats also produced increases in both the time spent and number of entries made into the open arms of the EPM [244] . In HAB rats, where increases in vasopressinergic system are observed in the PVN, administration of d(CH 2 ) 5 Tyr(Me)AVP into the PVN decreases similar anxiety behaviors in the EPM [167] . In contrast, the mixed V 1 R/V 2 R antagonist d(CH 2 ) 5 -D-Tyr(Et)AVP, administered locally into the lateral septum, failed to produce an anxiolytic-like effect on shock-probe burying behavior or activity in the EPM, suggesting a functional counteraction with the V 2 R subtype [245] .
Functional genomics approaches are in agreement with the evidence above, and have provided additional evidence in support of a role for V 1 R in mediating anxiety behaviors. Knock-down of V 1 R receptor expression in the septum with antisense oligonucleotides leads to a reduction in anxietyrelated behaviors in rats [116] . In a recent publication, Bielsky et al. report that V 1 R knockout mice exhibit an anxiolytic-like phenotype in the EPM, light/dark, and open field tests of anxiety behavior when compared to wild-type animals [246] . Increasing V 1 R expression using a adenoassociated viral vector delivery approach, Pitkow et al. produced selective increases in V 1 R gene expression in the ventral pallidum of prairie voles (M. ochrogaster) [247] . Following delivery, these animals displayed increased V 1 R binding that was commensurate with significant decreases in time spent in the open arms of the EPM, consistent with an anxiogenic-like effect [247] . Results of these studies suggest involvement of V 1 R in mediating AVP effects on anxiety behaviors, and suggest the potential for functional antagonism of V 1 R represents as a mode of action to achieve anxiolysis.
Further examination of evidence in the literature indicates the influence of V 1 R on behaviors related to the anxiety disorder subtype, OCD. Much of this support originates from evidence implicating V 1 R in stereotyped behaviors, which have been considered ethological correlates of OCD in humans. In hamsters, microinjections of V 1 R antagonists d(CH 2 ) 5 Tyr(Me)AVP or dPenTyr(Me)AVP into the septum produced dose-dependent decreases in AVPinduced flank marking behavior [248] . Bielsky et al. have demonstrated that stereotypy of scratching and repetitive grooming elicited by central administration of AVP is absent in male V 1 R knockout mice, suggesting the requirement of this receptor in mediating these behaviors [246] .
Autism
Animal studies have clearly indicated the importance of V 1 R in mediating AVP effects on social recognition. This has been reiterated by recent investigation of V 1 R knock-out mice, which exhibit profound impairments in social recognition [246] . Based on this, the authors suggest the relevance of V 1 R as a therapeutic target for some psychiatric disorders that feature impairments in social cognition, namely autism. Although clinical data has yet to be presented which supports the involvement of vasopressinergic function in autistic disorders, a preliminary report by Kim et al. has identified a transmission disequilibrium between autism and a microsatellite polymorphism in V 1 R [249] .
V 2 R
Clinical interest has historically focused on the V 2 R for it role in mediating the effects of AVP on the kidney. Peptide agonist analogs of AVP (e.g. DDAVP, DGAVP) have been used to treat diabetes insipidus. Additionally, a large number of small molecule V 2 R antagonists (e.g. OPC-41061, VPA-985, SR121463), also known as 'aquaretics', have been developed for clinical indications such as congestive heart failure, SIADH, hyponatremia, nephritic syndrome, hypertension, Meniere's disease, and diabetic neuropathy [250] . Research has also focused on the utility of targeting extrarenal V 2 R sites for ocular hypertension (glaucoma) [251] . Despite its predominant role in the periphery, V 2 R expression has been reported in the CNS, and peptide analogs of AVP, which are selective for V 2 R, have been widely investigated in both animals and humans. Evidence from these studies support the relevance of V 2 R as a therapeutic target for several CNS indications, particularly cognitive disorders.
Memory and Cognition
The majority of clinical studies investigating the effects of AVP analogs on memory and attention in humans involved the V 2 R-selective agonist DDAVP. (see Born et al. for review [13] ) These studies generally point to an enhancing effect for AVP on memory and cognition that is mediated, in part, by V 2 R receptor expression within the CNS.
Psychotic Disorders (Schizophrenia)
In clinical trials described above, patients with schizophrenia showed significant improvements of negative symptomatology with DDAVP therapy, in addition to improvements of short-to medium-term memory [231, 232] .
V 3 R
Historically, the absence of V 3 R-selective reagents has made it difficult to elucidate the functional contributions of this receptor subtype central vasopressinergic function. In the past couple of years, however, the synthesis of several V 3 R-selective reagents, such as the agonist d [Cha 4 ]AVP and antagonist SSR149415, have been reported [252, 253] . Investigation into the effects of SSR149415, in particular, has provided valuable new insights into the importance of this receptor subtype to the behavioral and neuroendocrine adaptation to stress. Moreover, proof-of-concept studies with SSR149415 in animal models of human psychiatric disease have provided compelling evidence supporting the V 3 R subtype as a molecular target several psychiatric conditions, particularly depression (see review [254] ).
Depressive Disorders
V 3 R antagonism with SSR149415 produces antidepressant-like activity in a variety of behavioral paradigms. The characteristic degradation of physical state in mice subjected to chronic mild stress is reversed by repeated administration of SSR149415, an antidepressant-like effect which was similar to the antidepressant fluoxetine [254] . The stress of the forced swimming test (FST) in rats leads to a depressivelike increase in immobility, which is reduced by SSRIs or SNRIs. In the FST, blockade of V 3 R with SSR149415 produces dose-dependent reductions in immobility time [179] . These antidepressant-like effects of SSR149415 in rats subjected to the FST were also observed following hypophysectomy, suggesting that V 3 R effects on behavior may not be dependent on the established influence of V 3 R over corticotroph function and the regulation of the HPA axis [179] .
The V 3 R subtype is the principle AVP receptor subtype expressed on corticotrophs of the anterior pituitary and as such is considered sine qua non to vasopressinergic control of ACTH release and HPA axis responsiveness. This importance of V 3 R to HPA activity is emphasized by observations from a recent report on V 3 R knockout mice (V 3 R -/-) [255] . V 3 R -/-mice exhibit marked reductions in both AVP-and stress (forced swimming)-induced release of ACTH from the anterior pituitary compared with wild type controls (V 3 R +/+ ). Under resting conditions, circulating levels of ACTH are also reduced in V 3 R -/-mice compared to V 3 R +/+ animals. Consistent with this, SSR149415 inhibits both hormone-(CRF + AVP) and stress (immobilization)-induced increases in plasma ACTH levels [252, 253] . The importance of targeting HPA axis hyperactivity in patients with depression and stress disorders is already implicit in the efforts pharmaceutical companies have already placed on developing antagonists of the CRF1 receptor [256, 257] .
The antidepressant potential of V 3 R antagonism has been further substantiated by in vivo microdialysis studies, which demonstrate that acute systemic challenge with SSR149415 leads to robust and dose-dependent increases in extracellular norepinephrine (NE) in the rat frontal cortex [258] . Disturbances in monoaminergic (NE, serotonin, dopamine) neurotransmission are commonly thought to participate in the underlying pathophysiology of depression and other stress-related disorders [259] . Whether by increasing monoamine synthesis (L-tryptophan), by preventing reuptake of monoamines (NRIs, SSRIs) or preventing the breakdown of monoamines (MAOIs), antidepressant agents derive therapeutic efficacy from, and are classified by, their ability to improve these deficiencies in monoamine neurotransmission [260] [261] [262] .
V 3 R antagonism with SSR149415 has been recently reported to prevent reductions in hippocampal (dentate gyrus) neurogenesis induced by chronic mild stress in mice [263] . Although direct evidence has yet to establish a causal association between neurogenesis and stress disorders such as depression, this phenomena has been increasingly viewed as a potential target for therapeutic development [264, 265] . 
Anxiety Disorders
The relevance of V 3 R to the regulation of anxiety behaviors is well supported by the behavioral effects of SSR149415 in both classical and atypical animal models of anxiety. SSR149415 produces increased punished crossings in the four-plates test (mice), percent entries into the open arms of the elevated plus-maze (rats), fear-potentiated startle (rats), Vogel conflict (rats), and social interaction (gerbils), all suggestive of an anxiolytic-like effects for V 3 R antagonism [179] .
In vivo microdialysis studies have demonstrated that acute systemic challenge with the SSR149415 (10 mg/kg, i.p.) produces robust and dose-dependent increases in extracellular gamma-aminobutyric acid (GABA) concentrations in the rat frontal cortex [258] . Alterations in GABAergic neurotransmission have been implicated in the pathophysiology of anxiety disorders (generalized anxiety disorder, post-tramatic stress disorder, and panic disorder) [266] . Clinically effective classes of anxiolytic compounds such as the benzodiazepines selectively target the central GABAergic system Anxiolytic-like effects of SSR149415 observed in the Punished Drinking Test (rats) can be blocked by co-administration with the benzodiazepine receptor (GABA) antagonist flumazenil, providing additional support to the involvement of V 3 R in modulating GABAergic neurotransmission. [179] V 3 R may also be a target of interest form the treatment of acute stress disorder, which is a subtype of anxiety disorders. In a variety of paradigms used to model acute stress in animals, SSR149415 displays anti-stress properties similar to clinical reference compounds such as diazepam and fluoxetine. Locomotor activity is significantly reduced by SSR149415 in mice subjected to the conditioned fear stress (paired foot shocks) [267] . SSR145419 also produces dosedependent decreases in both sonic and ultrasonic vocalizations (distress calls) of guinea-pig pups that have been separated from their mother, as well as significant decreases in the stress effects of social defeat (resident male aggression) on EPM performance in mice [179, 268] . In the Mouse Defense Test Battery, SSR149415 also produced a significant reduction in defensive aggression (sonic vocalizations, upright posturing, biting) by mice subjected to forced contact with a natural predator (Long Evans rat), a behavior which has been considered to be ethologically relevant to aspects of stress disorders in humans [179, 269] .
Together the evidence supporting the targeting of the V 3 R receptor for psychiatric indications is quite compelling, particularly with respect to mood (depression) and anxiety disorders. Side effect liabilities associated with V 3 R antagonists remain difficult to predict at the moment. This reflects the lack of understanding for the physiological significance, if any, of peripheral V 3 R expression. It is important to note that preliminary studies with SSR149415, aimed at evaluating standard safety concerns, suggest that antagonism of the V 3 R does not produce any obvious untoward side effects. SSR149415 fails to produce depressant effects on the rotorod, in the traction test, or on spontaneous activity in mice [179] . SSR149415 also failed to modify modify EEF sleep patterns in rats. A lack of effect was observed on food intake or weight gain in obese (ob/ob) or lean female mice, or normoglycemic mice and rats [270] . The mild impairments in social recognition observed in V 3 R -/-mice suggest that a closer examination of V 3 R antagonists influence over cognitive functions is warranted [271] .
CONCLUSIONS
From the evidence presented in this review, it is evident that AVP exerts a wide range of effects on CNS-mediated functions, in addition to the well-known endocrine effects of this neuropeptide on peripheral physiology. These central effects are mediated through a network of vasopressinergic fibers within the CNS that are anatomically distinct from those involved in release of AVP from the posterior pituitary into peripheral circulation. Through this central vasopressinergic system, AVP acts as a neuromodulator/neurotransmitter involved in the regulation of learning and memory, social behaviors, HPA reactivity, thermoregulation, and other autonomic functions.
Although clinical interest has historically focused on the peripheral effects of AVP, over 30 years of clinical investigation and hypothesis testing in animal models of human behavior reviewed here clearly implicate vasopressinergic disturbances in human psychiatric disease. The evidence presented above also implies that AVP receptor subtypes may represent valuable molecular targets in the ongoing efforts of pharmaceutical companies to develop innovative therapeutics for psychiatric illnesses. The opinion here is that, despite the rationale, these opportunities have been underexploited.
Investigation has clearly defined a role for V 1 R in social behaviors, and provided evidence that supports antagonism of this receptor as a novel approach for the treatment anxiety disorders. Numerous clinical trials, and evidence from animal studies, have established the therapeutic potential for V 2 R agonists in the treatment of cognitive disorders, particularly those involving impairments in memory. But at the moment, V 3 R appears to be the most tractable target of the AVP subtypes from a psychiatric drug discovery perspective. This is due in large part to the extensive preclinical evaluation of the first non-peptide V 3 R antagonist SSR149415 in animal models of human psychiatric disease.
With increased interest in the AVP receptors as therapeutic targets for the development of psychopharmaceuticals the field can anticipate the next generation of subtype-selective small-molecule compounds which feature improvements in orally-availability and blood-brain penetrance for reaching centrally expressed AVP receptor subtypes. In addition to realizing the potential opportunities for novel classes of therapeutics for debilitating psychiatric diseases, the generation of such compounds undoubtedly holds the promise of arming the field with pharmacological tools necessary for resolving the many remaining questions of central vasopressinergic system function.
